Skip to Content

Press Releases

Press Releases

Sep 20 2017
Intec Pharma to Participate in the Ladenburg Thalmann 2017 Healthcare Conference
JERUSALEM, September 20, 2017 /PRNewswire/ -- Intec Pharma Ltd. (NASDAQ and TASE: NTEC) today announced that management will participate in the Ladenburg Thalmann 2017 Healthcare Conference to be held September 26, 2017 at the Sofitel Hotel in New York City.
Sep 08 2017
Intec Pharma to Participate in the 19th Annual Rodman & Renshaw Global Investment Conference
JERUSALEM, September 8, 2017 /PRNewswire/ -- Intec Pharma Ltd. (NASDAQ and TASE: NTEC) today announced that management will participate in the 19th Annual Rodman & Renshaw Global Investment Conference to be held September 10-12, 2017 at the Lotte New York Palace Hotel in New York City.
Sep 01 2017
Intec Pharma to Participate in BioCentury's 24th Annual NewsMakers in the Biotech Industry Conference
JERUSALEM, September 1, 2017 /PRNewswire/ -- Intec Pharma Ltd. (NASDAQ and TASE: NTEC) today announced that management will participate in BioCentury's 24th Annual NewsMakers in the Biotech Industry Conference to be held on September 8, 2017 at the Millennium Broadway Hotel & Conference Center
Aug 21 2017
Intec Pharma Announces Closing of $57.5 Million Public Offering of Ordinary Shares
JERUSALEM, August 21, 2017 /PRNewswire/ -- Intec Pharma Ltd. (NASDAQ and TASE: NTEC) today announced the closing of its previously announced offering of approximately 12.2 million of its ordinary shares, at a public offering price of $4.70 per ordinary share, which included a full exercise by the
Aug 16 2017
Intec Pharma Announces Pricing of $50.0 Million Public Offering of Ordinary Shares
JERUSALEM, August 16, 2017 /PRNewswire/ -- Intec Pharma Ltd. (NASDAQ and TASE: NTEC) today announced the pricing of an underwritten public offering of approximately 10.6 million of its ordinary shares at a public offering price of $4.70 per ordinary share.
Aug 09 2017
Intec Pharma Reports Financial Results for the First Six Months of 2017
JERUSALEM, Aug. 9, 2017 /PRNewswire/ -- Intec Pharma Ltd. (Nasdaq: NTEC) (TASE: NTEC), a clinical-stage biopharmaceutical company focused on developing drugs based on its proprietary Accordion Pill™ (AP) platform technology, today reported financial results for the six months ended June 30, 2017.
Jul 27 2017
Intec Pharma Promotes Nadav Navon, Ph.D. to Chief Operating Officer
JERUSALEM, July 27, 2017 /PRNewswire/ --  Intec Pharma Ltd. (Nasdaq, TASE: NTEC), a clinical stage biopharmaceutical company focused on developing drugs based on its proprietary Accordion Pill™ (AP) platform technology, announces the promotion of Nadav Navon, Ph.D., Executive Vice
Jul 19 2017
Intec Pharma Granted Patent in Hong Kong for Accordion Pill™ Carbidopa / Levodopa
JERUSALEM, July 19, 2017 /PRNewswire/ -- Intec Pharma Ltd. (NASDAQ, TASE: NTEC), a clinical-stage biopharmaceutical company focused on developing drugs based on its proprietary Accordion Pill™ platform technology, announces that the Patent Registry Intellectual Property Department of Hong Kong has
Jul 19 2017
Intec Pharma Granted Patent in Hong Kong for Accordion Pill™ Carbidopa / Levodopa
JERUSALEM, July 19, 2017 /PRNewswire/ -- Intec Pharma Ltd. (NASDAQ, TASE: NTEC), a clinical-stage biopharmaceutical company focused on developing drugs based on its proprietary Accordion Pill [ TM ]  platform technology, announces that the Patent Registry Intellectual Property Department of Hong
Jul 10 2017
Intec Pharma Appoints U.S. Life Sciences Executive and Vice Chairman Jeffrey A. Meckler as Chief Executive Officer
JERUSALEM, July 10, 2017 /PRNewswire/ -- Intec Pharma Ltd. (Nasdaq: NTEC, TASE: NTEC), a clinical stage biopharmaceutical company focused on developing drugs based on its proprietary Accordion Pill™ platform technology, announces the appointment of Jeffrey A.
Displaying 31 - 40 of 77